Local relapse (n) | | | | |
PSA recurrence/persistence | | | 30/71 (42.3%) | <0.001 |
Total | | | | |
rcTx | 33/71 (46.5%) | 8/71 (11.3%) | | |
rcT0 | 33/71 (46.5%) | 53/71 (74.6%) | | |
rcT+ | 5/71 (7.0%) | 10/71 (14.1%) | | |
Lymph node spread (n) | | | | |
All patients | 15/121 (12.4%) | 39/121 (32.2%) | 25/121 (20.7%)* | <0.001 |
Initial diagnosis | 5/50 (10.0%) | 8/50 (16.0%) | 5/50 (10.0%) | |
Intern iliac vessels | — | 2/50 (4.0%)† | | |
Extern iliac vessels | 5/50 (10.0%)† | 5/50 (10.0%)† | | |
Presacral | 1/50 (2.0%)† | 2/50 (4.0%)† | | |
Obturatoric vessels | — | 2/50 (4.0%)† | | |
Other | — | 1/50 (2.0%)† | | |
PSA recurrence/persistence | 10/71 (14.1%) | 31/71 (43.7%) | 20/71 (28.2%) | |
Intern iliac vessels | 3/71 (4.2%)† | 10/71 (14.1%)† | | |
Extern iliac vessels | 3/71 (4.2%)† | 13/71 (18.3%)† | | |
Presacral | 3/71 (4.2%)† | 12/71 (16.9%)† | | |
Obturatoric vessels | — | 2/71 (2.8%)* | | |
Other | 2/71 (2.8%)† | 8/71 (11.3%)† | | |
Distant metastases (n) | | | | |
All patients | 26/121 (21.5%) | 41/121 (33.9%) | 23/121 (19.0%)* | <0.001 |
Initial diagnosis | 3/50 (6.0%) | 5/50 (10.0%) | 7/50 (14.0%) | |
Lymph nodes | 2/50 (4.0%) | 3/50 (6.0%)† | | |
Bone | 1/50 (2.0%) | 3/50 (6.0%)† | | |
Other | — | — | | |
PSA recurrence/persistence | 23/71 (32.4%) | 36/71 (50.7%) | 16/71 (22.5%) | |
Lymph nodes | 2/71 (2.8%) | 8/71 (11.3%)† | | |
Bone | 18/71 (25.4%) | 27/71 (38.0%)† | | |
Other | 3/71 (4.2%) | 3/71 (4.2%)† | | |